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Human schistosomiasis is a chronic inflammatory disease caused by blood fluke worms
belonging to the genus Schistosoma. Health metrics indicate that the disease is related to
an elevated number of years lost-to-disability and years lost-to-life. Schistosomiasis is an
intravascular disease that is related to a Th1 and Th2 immune response polarization, and
the degree of polarization affects the outcome of the disease. The purinergic system is
composed of adenosine and nucleotides acting as key messenger molecules. Moreover,
nucleotide-transforming enzymes and cell-surface purinergic receptors are obligatory
partners of this purinergic signaling. In mammalian cells, purinergic signaling modulates
innate immune responses and inflammation among other functions; conversely purinergic
signaling may also be modulated by inflammatory mediators. Moreover, schistosomes also
express some enzymes of the purinergic system, and it is possible that worms modulate
host purinergic signaling. Current data obtained in murine models of schistosomiasis
support the notion that the host purinergic system is altered by the disease. The
dysfunction of adenosine receptors, metabotropic P2Y and ionotropic P2X7 receptors, and
NTPDases likely contributes to disease morbidity.Schistosomiasis
Human schistosomiasis (or bilharzia) is a chronic inflamma-
tory disease caused by blood fluke worms belonging to the
genus Schistosoma. According to the World Health Organi-
zation (WHO), more than 200 million people worldwide suffer
from chronic schistosomiasis and approximately 800of Rio de Janeiro, Av. Car
.br, silva.claudiamartins.
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/by-nc-nd/4.0/).million people live in schistosomiasis-endemic areas. Schis-
tosomiasis is therefore considered to be one of the world's
most prevalent infectious diseases (http://www.who.int/
schistosomiasis/en/, as of June 2016). This neglected tropical
disease largely affects people living in poverty. The Disability-
Adjusted Life-Year (DALY), a time-based measure used as a
healthmetric, considers the number of years lost-to-disabilitylos Chagas Filho, 373 CCS Room J-17, 21941-902, Rio de Janeiro, RJ,
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recent data, schistosomiasis is related to a DALY of 3.3 million
and is associated with a substantial socioeconomic burden in
low- and middle-income countries [1,2].Fig. 1 e Illustrated schematic of the Schistosoma lifecycle.
Infected snails (D) release the larval form cercariae (E) in a
body of water. Human schistosomiasis starts after the
cercariae penetration the skin in direction to a venule or
lymphatic vessel (A). The worms navigate through the
cardiovascular system reaching vessels from the gut (S.
mansoni and S. japonicum) or bladder (S. hematobium). Adult
worms mate, and females lay hundreds of eggs daily (B). The
eggs release miracidium in the water (C), which is infective
for snails. The asexual reproduction of a miracidium
generates several cercariae that are released via the snail.
Adult male worms are about 1 cm long. They have smooth
muscle layers beneath the external tegument and two
suckers by which they attach to the blood vessel wall.
Reproduced from Ref. [3] with permission.Schistosoma lifecycle
Themajority of cases of human schistosomiasis are caused by
three main species of the genus Schistosoma: Schistosoma
mansoni, Schistosoma japonicum and Schistosoma hematobium.
Each species has a geographical and pathological importance:
S. mansoni (in Africa, the Middle East and the Americas) and S.
japonicum (in South and Middle Asia) cause intestinal and
hepatosplenic schistosomiasis; S. hematobium (in Africa and
the Middle East) causes urinary schistosomiasis [3].
The parasite lifecycle includes an intermediate (snail) and
a definitive (mammalian) host [3] and shows remarkable fea-
tures of adaptive biology. Infected aquatic snails release
cercariae that are highly infective for the definitive host. The
human infection starts when an individual comes into contact
with a body of water infested with cercariae. These larval
forms explore host thermostatic gradient or chemical signals,
attach to the epidermis and penetrate human skin. Both the
head and acetabular cercarial glands secrete enzymes such as
elastases that are serine proteases and immunomodulators
involved in epidermis and dermis penetration [4]. After
entering the dermis, cercariae must reach a venule or a
lymphatic vessel while transforming into schistosomula [5,6].
Perivascular CD4þ T cells are found in human skin accompa-
nied by interleukin (IL)-7 production that seems to favor skin
invasion and worm survival [7]. Next, during schistosomula
migration via the heart and lungs to their specific vascular
site, they undergo a series of structural and physiologic
transformations before becoming adults. Adult worms mate
in the vessels of the intestine (S. mansoni and S. japonicum) or
the vesical plexus around the bladder (S. hematobium) and then
become permanent pairs and start oviposition. Each egg
contains amiracidium larva and secretes proteolytic enzymes
that favor egg migration into the lumen of the intestine or
bladder; these eggs are then consequently excreted in feces or
urine, respectively. In due course, eggs that are not eliminated
are trapped in the organs and result in immune responses.
Voided eggs, once in contact with freshwater, release the free-
swimming miracidium that infects snails and a new lifecycle
is started [Fig. 1]. The asexual reproduction of miracidium in
the snails produces hundreds to thousands of cercariae [3]. In
light of the schistosoma lifecycle, the host immune system is
actually challenged by the three stages of the parasite
(cercariae, migrating schistosomula and adult worms) and
also by eggs [8,9].Host immunologic responses during schistosomal infection
Human and schistosomes co-evolved, which favored worm
survival in the host [10]. Some abilities of schistosomes have
been noted to favor parasite survival (e.g., the capacity to
regenerate the outer tegument, molecular mimicry, acquire-
ment of host antigens and immunomodulation) [8]. Murine
infection with S. mansoni resembles human infection, andtherefore, several lines of data have derived from this exper-
imental model [8].
Worm- and egg-derived antigens recognized by T and B
lymphocytes modulate host immune system by down- or
up-regulating cellular and humoral immune responses
[8,10e17]. Briefly, the host immune response polarizes to a
Th1-cell response in the first five weeks after infection. At
this stage, Th1 cells and peripheral mononuclear blood cells
produce large amounts of tumor necrosis factor (TNF)-a,
interferon (IFN)-g, IL-1 and IL-6. In the very beginning of the
infection, lung immune responses are able to kill schisto-
somula [11]. However, Trottein and colleagues [18] showed
that schistosomula reduces lung vascular cell adhesion
molecule (VCAM)-1 expression and leukocyte recruitment,
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are driven to an anti-inflammatory phenotype. As the
worms mature, mate and start egg deposition, a largely Th2
response emerges with the production of cytokines such as
IL-4, IL-5 and IL-13, as well as eosinophilia and intestinal
and mesenteric mastocytosis, and high circulating levels of
IgE [8]. IL-17 production is also tightly regulated by IFN-g and
IL-4. The capacity of limiting the pro-inflammatory Th1
response is essential for host survival. In murine model, the
infection of IL-4 knockout mice (a model of polarized Th1
response) resulted in tissue damage and mortality [8,19e22].
Natural regulatory T cell (Treg) also modulates Th cell re-
sponses during schistosomiasis [23].
Macrophages are important cells for host defense that may
be primed by signals from the extracellular milieu. Each sub-
set of macrophage phenotype has distinct patterns of gene
expression producing pro- and anti-inflammatory mediators
[24]. The different subsets of macrophage phenotypes include
the classically [cMФ (classically activated macrophage); M1
macrophages] or alternatively activated phenotypes [aaMФ
(alternatively activated macrophage); M2 macrophages].
Furthermore, macrophages may express M1 and M2 markers
resulting in intermediate polarization subsets [24].
Concerning schistosomiasis, aaMФ are typically found in
the vicinity of granuloma and Th2 cytokines, and express the
enzyme arginase 1 (Arg-1) that limits Th2-driven fibrosis [21].
Infected mice with polarized Th1 responses exhibit reduced
aaMФ and granuloma formation, high inducible nitric oxide
synthase (iNOS) responses and mortality due to severe intes-
tinal and liver pathology [25e29].
Eggs lodged in tissues may cause necrosis and host de-
fenses form a granuloma around the eggs in order to contain
the insult, although the granuloma may also be deleterious to
host physiology due to fibrosis and portal hypertension
[12,27]. The morbidity of the chronic disease takes into ac-
count the level of fibrosis and inflammation [8,22]. According
to previous data using a murine model, IL-13 plays an
important role in liver fibrosis and Th1 response mediators
limit such action [30,31]. Patients with severe fibrosis were
found to have high levels of TNF-a, IL-5, IL-10 and IL-13; pa-
tients with mild fibrosis showed high IFN-g levels [27]. Inter-
esting, although it is believed that Th1 and Th2 responses are
mutually exclusive phenotypes of CD4þ helper T cell, Deaton
and colleagues [32] identified IFN-gþ IL-4þ cells in S. mansoni-
infected mice. It is possible that a balance between Th1 and
Th2 cytokines may counter-regulate the excessive fibrosis
related to a prolonged Th2 immune response [32] and deter-
mine the outcome of the disease. Furthermore, extra-
immunological effectors might also modulate immune
responses during schistosomiasis [27].
Schistosoma biology: evidence of the worm purinergic
system
Considering the three main species of schistosomes, molec-
ular biology data referred initially to S. mansoni and S. japoni-
cum; complete genome sequences of these species were
published in 2009 [33,34]. Data pertaining to the genome of S.
hematobiumwere published some years later [35]. By relying on
proteomic data and bioinformatics, it has been possible toconstruct schistosome phylogenetic trees of proteins encoded
by the genome, the so-called phylome [4]. According to cur-
rent knowledge, S. mansoni is more closely related to S. hem-
atobium (89.4%) than to S. japonicum (67%) [4]. The genomes
were revised and are available in a database (SchistoDB; [36]).
Additionally, the number of known proteins is higher for S.
mansoni than for the other two species [37].
According to the genome of S. mansoni, the worm has at
least four genes related to P2X receptors subunits [33]. Previ-
ously, the gene of a P2X-like receptor (schP2X) was cloned and
heterologously expressed in Xenopus oocytes. Electrophysio-
logical studies have revealed that bothATP and theATP analog
benzoyl-ATP (BzATP) evoked inward currents at these recom-
binant schP2X receptors that were blocked completely by sur-
amin and partially by pyridoxalphosphate-6-azophenyl-20,40-
disulfonic acid (PPADS) (100 mM) [38]. Furthermore, high
agonist concentrations desensitized the receptor [39]. A com-
parison of the amino acid sequence between schP2X and
human P2X(1-7) receptors revealed an identity of 25.8% for P2X7
and 36.6% for P2X4 receptors [38] and 36% for P2X5 [39]; the
latter authors referred to the receptor as SmP2X. This level of
identity is remarkable since an acoelomate primitive platy-
helminth has been considered to be the organism fromwhich
many other phyla have evolved [40], and some Schistosoma
genesmaybe ancestors ofmammalian genes [41].Moreover, S.
mansoni expresses other enzymes and channels involved in
intracellular Ca2þ homeostasis that were initially identified by
functional assays including ATPases and Ca2þ channels
[42e46] as well as receptors for important neurotransmitters
such as GABA, glutamate and acetylcholine [47e49]. These
functional data have been corroborated by the genomic
description of both S. mansoni [33] and S. japonicum [34].
Purines are considered to be one of the most primitive
chemical messengers in the animal kingdom [50]. Schisto-
somes take advantage of host signaling pathways. Unlike
mammalian cells, schistosomes are unable to synthesize pu-
rine nucleotides de novo. Therefore, they depend on host-
preformed purines and salvage pathways for the conversion
of bases and nucleosides back into nucleotides [51].
It has been suggested that nucleotide hydrolysis occurs in
the tegument (external face) of the worms near the site of the
uptake of the products of such hydrolysis [52,53].
The tegumental nucleotide-metabolizing ecto-enzymesare
alkaline phosphatase (smAP), ecto-phosphodiesterase
(smPDE) and ecto-ATP diphosphohydrolase (also known as
apyrase or E-NTPDase) (smATPDase) [54,55]. smATPDase1 is
expressed in schistosomula, female and male worms and
seems to hydrolyze ATP and ADP equally (i.e., the enzyme has
the same affinity for both substrates) [55,56]. On the other
hand, thehomologsmATPDase2 isnotpresent in the tegument
but is highly expressed in eggs (compared with worms), and
the evidence obtained so far has not shown that this enzyme is
responsible for the hydrolysis of exogenous (host-derived) ATP
or ADP [55]. Nevertheless, a synthetic peptide belonging to
smATPDase2 was shown to be immunogenic when injected
intomice [57].Moreover, an IgGantibody fromschistosomiasis
patients showed cross-immunoreactivity with a domain from
smATPDase2 [58], which could be useful for diagnostic pur-
poses or vaccine development. Furthermore, adenosine
monophosphate (AMP) seems to be hydrolyzed by smAP [55].
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inate adenosine to inosine and convert adenosine to adenine,
which suggests that the worms also possess adenosine
deaminase (ADA) and adenosine phosphorylase [51,59].
However, the conversion of adenosine to AMP by adenosine
kinase seems to be minor [50]. Moreover, schistosomes are
also able to convert the adenine analog 2-fluoroadenine into 2-
fluoroadenine nucleotides such as 2-fluoro ATP [60]. There-
fore, schistosomes also have adenine phosphoribosyl-
transferase and nucleoside kinases [51,61], and they
incorporate adenine into ATP in a higher rate than that of
mammalian cells [62,63]. Overall, schistosomes are able to
convert adenosine, adenine and inosine to AMP and ulti-
mately to ATP. In addition, inosine may also be converted to
inosine monophostate (IMP) and ultimately to GTP [51].
Since schistosomes have a purine salvage network, it has
been proposed that purine analogs could be potential anti-
schistosomal drugs. However, so far no such drug has been
shown to be both effective and safe for humans. A unique
antischistosomal drug in clinical use, praziquantel (at micro-
molar concentrations), is able to reduce both [3H]-adenosine
and [3H]-uridine worm uptake [64], but other mechanisms
such as the influx of Ca2þ, worm muscle paralysis, inhibition
of P-glycoprotein-like protein [a member of ATP-binding-
cassette (ABC) superfamily of proteins] and tegument rupture
have been noted as relevant for the pharmacological effect
[65e67]. However, there have been reports of resistance to
praziquantel, and the development of new drugs for this
neglected tropical disease is most welcome. In this context,
the worm purine nucleoside phosphorylase has been consid-
ered to be a putative new target for new antischistosomal
drugs [37].
Purinergic signaling
Cellular ATP was identified at the end of the 1920s [68].
Concomitantly, some initial evidence of a purine acting as a
chemical transmitter was also unveiled by the demonstrationFig. 2 e Purinergic receptors. Extracellular nucleotides mediate int
receptors (P2X) and metabotropic P2Y receptors. On the other han
The conversion of ATP to other nucleotides and adenosine is med
permission.that an organic compound isolated from animal tissues ex-
tracts exerted depressant effects on cardiac rhythm, blood
pressure and intestinal movements [69]. A large number of
independent studies contributed to the discovery and defini-
tion of the purinergic system, and its identification in in-
vertebrates (including S. mansoni) implied an earlier onset of
evolution [70e72]. In this context, it is possible that the co-
evolution of hosts and parasites has enabled the establish-
ment of a chronic infection.
The purinergic system is an important modulator of
innate immune response and inflammation [73]. In addition,
this system also regulates neurotransmission and the car-
diovascular system. The complexity of the purinergic system
encompasses a great variety of agonists, receptors and en-
zymes [74].
Adenosine and the nucleotides ATP, ADP, uridine 50-
triphosphate (UTP), uridine 50-diphosphate (UDP) and UDP-
glucose are key messenger molecules that mediate a wide
diversity of biological actions of purinergic signaling. More-
over, nucleotide-transforming enzymes and cell-surface re-
ceptors are obligatory partners in this purinergic signaling.
The International Union of Pharmacology (IUPHAR) Commit-
tee on Receptor Nomenclature and Drug Classification recog-
nizes distinct receptors pertaining to the purinergic system.
Receptors for extracellular adenosine and nucleotides can be
divided into three subfamilies: metabotropic purinergic P1
receptor (or A receptor; activated by adenosine), metabotropic
P2Y receptor (activated by ATP and other nucleotides) and
ionotropic ATP-gated P2X receptor. According to molecular
structure and functional data, adenosine P1 receptors can be
divided into four subgroups: A1, A2A, A2B and A3. On the other
hand, P2Y receptors can be divided into eight subgroups (P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14) and P2X re-
ceptors can be divided into seven (P2X1-7) subtypes [75e78]
[Fig. 2]. Furthermore, dinucleotide polyphosphates (NpnNs)
also modulate the purinergic system and consist of two nu-
cleotides linked by a polyphosphate bridge containing 2e7
phosphate groups. One of most studied classes of theseracellular signaling through cell surface ionotropic ATP-gated
d, adenosine receptors (A) are activated by adenosine (Ado).
iated by ecto-enzymes [76]. Reproduced from Ref. [122] with
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denosine tetraphosphate (Ap4A) was the first ApnA described
in mammalian tissues and, once in the extracellular milieu, is
also a modulator of some P2 receptors. Later, other ApnA
compounds were identified with distinct physiologic actions
[79,80]. Recently, a new family of adenine G protein-coupled
receptor has been characterized in rodents; this family has
been named P0-receptors [81].
Mammalian cells contain high concentrations of ATP (mM)
that can be released into the extracellular milieu. However,
given the diversity of cell types, different physiologic pro-
cesses of ATP release have been described such as regulated
vesicular exocytose and conductive/diffusional release (via
pore-forming connexin, pannexin and P2X7 receptor) or ABC
cassette transporters [74,82]. Other mechanisms have also
been described such as anion channel-mediated ATP release.
Moreover, ATP can be synthesized via plasmamembrane F(1)/
F(0)-ATP synthase. Alternatively, ATP may be released under
pathologic conditions causing tissue damage, cell death or
stress [74]. In such cases, ATP is recognized as a “damage-
associated molecular pattern” (DAMP). Uridine 50-triphos-
phate release may share some of these mechanisms [82e85].
Besides interacting with cell-surface purinergic P2 re-
ceptors, ATP (and other nucleotides) is also a substrate for
catabolizing ecto-enzymes (ecto-nucleotidases), thereby con-
trolling the availability of extracellular nucleotides and puri-
nergic P2 receptor signaling. Ecto-nucleotidases hydrolyze
nucleoside mono-, di-, or triphosphates, dinucleoside poly-
phosphates and produce nucleoside diphosphates, nucleoside
monophosphates, nucleosides, phosphate and inorganic py-
rophosphate (PPi) [76,85].
The major groups of ecto-nucleotidases are ecto-
nucleoside triphosphate diphosphohydrolases (E-NTPDases;
apyrase or CD39), ecto-50-nucleotidase (eN; CD73), ecto-
nucleotide phosphodiesterases/pyrophosphatase (E-NPP) and
alkaline phosphatases (APs). Thus far, E-NTPDases have been
considered to be the major ecto-nucleotidase of purinergic
signaling. They hydrolyze selectively nucleoside tri-
phosphates and diphosphates, generating nucleoside mono-
phosphate. In the case of AMP, it is a specific substrate for eN,
another important enzyme of the purinergic signaling, which
in turn generates adenosine. Eventually, NTPDases and eN are
co-expressed in the same cell [76].
NTPDases are expressed ubiquitously in eukaryotes. In
mammals, researchers have identified eight paralogs of
NTPDases; four of them (NTPDase1, NTPDase2, NTPDase3 and
NTPDase8) are cell surface enzymes. NTPDases4-7 are intra-
cellularly located; however, NTPDase5 and NTPDase6 may
eventually be secreted [76]. NTPDases1-3 and NTPDase8 hy-
drolyze nucleoside triphosphates and diphosphates, but the
affinity for the substrate varies according to enzyme subtype
and species. Human and murine NTPDase1 have equal affin-
ities for ATP and ADP; NTPDase2 has higher affinity for ATP
than for ADP, and NTPDase3 hydrolyzes ATP to AMP [76,86]. S.
mansoni seems to express a protein closely related to
NTPDase1 and NTPDase5 [76]. Of note, S. mansoni outer teg-
umental smATPDase I, smAP and smPDE are considered to be
candidate virulence factors with the potential to modulate the
host's immune system [12].Host purinergic signaling during schistosomal infection
Besides the salvage nucleotide metabolism, it is possible that
schistosomes may modulate host immune responses and
platelet aggregationmediated by purinergic signaling [55]. The
presence of intravascular parasites may damage endothelial
cells and induce nucleotide release (DAMPs). The worm ca-
pacity to reduce ATP and ADP concentrations around them-
selves may limit host inflammation and platelet aggregation;
adenosine formation may favor vasodilation and worm
migration [54], and eventually worm's metabolism [52,53].
Human and mice schistosomiasis is related to thrombocyto-
penia. Additionally the tegumental smATPDase1 possibly
contribute to inhibit ADP-mediated platelet aggregation
[55,87].
A large amount of data about schistosomiasis has been
obtained using S. mansoni-infected mice. Important evidence
for the alteration of purinergic signaling during schistosomal
infection came from work by De Man and colleagues [88]. In
control mice, both adenosine and ATP attenuated the ileum
contraction induced by neural-released acetylcholine, but not
in response to carbachol (exogenous agonist). The adenosine
effect was blocked by the antagonist 8-phenyltheophylline
and mimicked by the agonist N(6)-cyclohexyladenosine,
implying the participation of the presynaptic A1 receptor.
Since the ATP effect was also blocked by the A1 receptor
antagonist, the authors suggested that ATP was converted to
adenosine to exert the inhibitory effect. According to the data,
the purinergic control of cholinergic neurotransmission by A1
receptor was compromised during infection with S. mansoni,
and increased ileum contraction was observed. During intes-
tinal inflammation, there is an increased number ofmast cells
close to themyoenteric neurons, and the continuous exposure
of A1 receptors to adenosine may lead to receptor desensiti-
zation. Chronic intestinal inflammation is related to alter-
ations of intestinal motility, and it is accordingly possible that
the enteric dysfunctional purinergic signaling contributes to
schistosomal morbidity [3].
Tissue insult recruits eosinophils as inflammatory effector
cells. The intracellular eosinophil granules contain preformed
cytokines, eosinophil peroxidase and cationic proteins that
may be released by degranulation and exocytosis. Alterna-
tively, the presence of intact eosinophil cell-free granules in
tissues is evidence of eosinophil necrosis [89]. However, such
extracellular granules are secretion-competent organelles
responsive to external stimuli [90].
Eosinophilia is a key feature of human schistosomiasis [10],
and some lines of evidence point to a capacity of eliminating
helminths. For instance, it has been shown that eosinophils
are able to invade dying schistosomes, and eosinophil granule
proteinsmay contribute to killing [91]. Using a reporter animal
model characterized by an eosinophil peroxidase-luciferase
(EPX-luc) transgenic mice, Davies and colleagues [91] showed
that there is increased eosinophilopoese in the bone marrow
and eosinophilia in the liver and intestine in response to both
worms and eggs during schistosomiasis.
Human and murine eosinophils (and other immune cells)
expressmRNA encoding several P2X and P2Y receptors [92]. In
addition, immunoreactivity against the P2Y12 receptor protein
Fig. 3 e Survival curves of S. mansoni-infected mice (black
line: C57BL/6 wild type; Red line: P2X7 receptor knockout
mice (P2X7RKO)). Newborn mice were infected and observed
for 9 weeks. Reproduced from Ref. [103] with permission.
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data additionally suggest the expression of human P2Y12 re-
ceptors since stimulation with the agonist ADP induced the
secretion of eosinophil peroxidase, which was selectively
reduced by the P2Y12 receptor antagonist MRS2395 [93]. In the
murinemodel, treatment of S. mansoni-infected mice with the
P2Y12 receptor antagonist clopidogrel reduced the size of liver
granuloma, collagen deposition, the number of infiltrated
eosinophils, IL-4 and IL-13 levels in liver homogenates
compared with infected, untreated animals. However, clopi-
dogrel did not interfere with Th2 polarization during schisto-
somiasis since the plasma levels of IL-13 were only slightly
reduced, and the IL-4 levels were not changed [93]. These data
suggest that pro-inflammatory P2Y12 receptor signaling takes
part in eosinophil migration to liver granulomas and may
contribute to fibrosis.
Co-infections with Schistosoma and bacteria, virus, pro-
tozoa or other helminths are known [94,95]. The association
among Salmonella infections and eventually bacteremia and
schistosomiasis has also been reported [95]. It is possible that
Th2 polarization plays a role in such co-infections [96].
Macrophages are resident phagocytic cells of the innate
immune system. They act as the first line of the host de-
fense against pathogens in non-adaptive responses and may
also contribute to adaptive immune responses, ultimately
leading to pathogen killing [97,98]. Moreover, during schis-
tosomiasis the degree of differentiation between cMФ and
aaMФ contributes to the level of inflammation and fibrosis
[25].
Purinergic P2X7 receptors are expressed on monocytes and
macrophages, regulate cytokine production, apoptosis, and
take part in inflammasome. These receptors are localized in
lipid rafts and therefore they interact with caveolin and also
modulate the activity of phospholipases A2, C and D [99]. P2X7
receptors activation by agonists such as ATP (mM) and the
analog BzATP induces a cation-specific channel opening along
with Ca2þ influx and Kþ efflux; moreover pore dilation allows
for the permeation of large molecules such as ethidium bro-
mide [99]. The activation of macrophage P2X7 receptors
stimulates the secretion of cytokines such as TNF-a and IL-1b,
but a disproportionate production may be detrimental in
chronic inflammation [100]. Moreover, macrophage P2X7 re-
ceptors may function as scavenger receptors for bacteria and
apoptotic cells [101]. Previous data with mice infected with S.
mansoni pointed to a reduced phagocytic and bactericidal ca-
pacity of peritoneal macrophages [102].
Using F4/80þ peritoneal macrophages from S. mansoni-
infected mice (in the beginning of the chronic phase), we
observed that both Ca2þ influx and cell permeabilization in
response to ATP and BzATP were reduced compared with
cells from control mice. Infected animals also exhibited
increased levels of transforming growth factor (TGF)-b1 [103].
While IFN-g increases P2X7 receptor expression [104], treat-
ment of peritoneal macrophages with TGF-b1 reduced cell
surface P2X7 receptor expression [103]. These data point to
reduced P2X7 receptor signaling in macrophages during
schistosomiasis. The infection of P2X7 receptor knockout
mice resulted in a reduced survival curve [Fig. 3], a finding
that suggests that these receptors are important to host
defense.In view of the reduced P2X7 receptor function it could be
expected a failure of host IL-1b expression in response to
pathogen. However, Ritter et al. [105] showed that egg-derived
soluble antigens (SEA) (i.e., “pathogen-associated molecular
patterns” (PAMPs)) stimulate IL-1b expression by dendritic
cells through a dectin-2 pathway.Moreover, the stimulation of
dendritic cells from P2X7 receptor knockout mice with SEA
also induced IL-1b expression suggesting that this signaling
does not depend largely on P2X7 receptor function. Thereby
this finding implicates that the infection influences directly
inflammasome activation [105].
The lumen of blood vessels and lymphatics is covered by
endothelial cells that are considered important regulators of
leukocyte adhesion, vascular permeability and mechanisms
of vascular contraction and dilation [106e108]. The intravas-
cular location of Schistosoma makes endothelial cells as first
target of the disease. Endothelial cells show remarkable
phenotypic heterogeneity and undergo epigenetic regulation
[106]. According to previous data with infected mice, endo-
thelial cells primed by schistosomiasis keep in culture the
acquired phenotype [109].
Under physiologic conditions, endothelial cells show an
anti-inflammatory phenotype. The constitutive production of
endothelial-derived NO plays an important role inhibiting
leukocyte adhesion, smooth muscle cell proliferation and
controlling vascular tone. Conversely, under pathologic con-
ditions endothelial cells become dysfunctional showing a
proadhesive phenotype and expressing adhesion molecules
important for leukocyte rolling, adhesion and transmigration
[108,110]. Of note, some cytokines found to be increased in
schistosomal infection, such as TNF-a and IL-13, have a
deleterious role on endothelial cell function favoring a pro-
inflammatory phenotype [110]. Accordingly, a reduced
expression of endothelial NOS (eNOS) during schistosomal
infection has been described characterizing an endothelial
dysfunction [109].
Purinergic system is present on endothelial cells. These
cells release ATP, express purinergic receptors and ecto-
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 3 1 6e3 2 5322nucleotidases [73,75,84]. Endothelial cells from different
vascular beds express several subtypes of purinergic P2Y re-
ceptors, including P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 receptors
[73,111,112]. Moreover, P2X4 and P2X7 receptors [73,113,114]
and NTPDases 1, 2 and 3 are also expressed [85,115].
Vascular P2X7 receptors activation induces endothelium-
dependent vasodilation [116] and constitutive NO production
in cultured endothelial cells [113]. However, excessive P2X7
receptor activation may lead to apoptosis [99]. Mesenteric
endothelial cells from S. mansoni-infected mice exhibited a
reduced Ca2þ influx and ethidium bromide uptake in response
to the agonist BzATP [113]. We found that the downregulation
of endothelial P2X7 receptor signalingwas related to a reduced
protein expression, which also reduced NO production in
response to ATP or BzATP. So far there is no evidence of a pu-
tative protection against endothelial cell apoptosis. Never-
theless, previouslywe showed thatATP-inducedproductionof
NO was compromised in cells from S. mansoni-infected mice,
and this endothelial dysfunction contributed to an increased
leukocyte adhesion, vascular inflammation and infiltration of
leukocytes in the peritoneal cavity [109] and portal vein [117].
The endothelial expressions of NTPDases 2 and 3 are
increased by schistosomal infection along with a higher hydro-
lysis of ATP, and ADP generation [115]. ADP is the endogenous
agonist of P2Y1 receptor, which is widely expressed through the
vascular system [73,81,111,112]. P2Y1 receptor induces the
expressionof adhesionmolecules suchas intercellular adhesion
molecule (ICAM)-1 thereby having a pro-inflammatory effect
[118], and ICAM-1 has been noted as themost relevant adhesion
molecule for schistosomiasis-related portal inflammation [119].
In the infected group, the increased extracellular concentration
of ADP was accompanied by an increased basal leukocyte
adhesion to endothelial cells as compared to control group. The
P2Y1 receptor agonist 2-methylthioATP (2-MeSATP) also
increased leukocyte adhesion. However, the selective P2Y1 re-
ceptor antagonist MRS2179 blocked 2-MeSATP effect, and also
returned basal leukocyte adhesion to control levels suggesting
an upregulation of basal P2Y1 receptor signaling during this
stage of schistosomiasis [115].
Data from another model of S. mansoni infection (hamster)
showed a reduced content of ATP and an increased content of
ADP in liver from infected animals compared with controls
[120]. The altered ATP/ADP ratio could also reflect alterations
of the purine metabolism during the disease.
Chronicmansonic schistosomiasis is related to a repertoire
of worm- and host-derived immunomodulators culminating
in intestinal and hepatosplenic alterations [3,8,22]. According
to murine model, ADP seems to control liver and mesenteric
schistosomal inflammation [92,115]. Although the expression
of P2X7 receptor andNTPDases 2 and 3were differently altered
by this stage of schistosomiasis, the expressions of P2Y1 re-
ceptor, NTPDase 1 and 50ecto-nucleotidase were not altered in
the same model [115]. Therefore, these data suggest that the
disease affects in different ways the receptors and enzymes of
the purinergic system.
If translated to the clinics, the purinergic signaling alter-
ations observed during murine schistosomiasis could
contribute to schistosomal morbidity. Moreover, current data
suggest that P2Y1 and P2Y12 receptors could be pharmacologic
targets to reduce chronic schistosomal inflammation andmorbidity. Actually, P2Y receptors have been considered as
potential pharmacologic targets in several other chronic in-
flammatory conditions [121].Conclusion
Schistosomiasis-related chronic inflammation promotes host
intestinal and liver alterations. Current data obtained with
experimental models support the notion that host purinergic
system is altered by schistosomiasis. The dysfunction of
adenosine receptors, metabotropic P2Y receptors, ionotropic
P2X7 receptors, and NTPDases likely contributes to some dis-
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